<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" bill-type="olc" dms-id="A1" public-private="public" slc-id="S1-KEL19847-YPV-VM-5BB"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>116 S2650 IS: Medicare Prescription Drug Savings and Choice Act of 2019</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2019-10-21</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>116th CONGRESS</congress><session>1st Session</session><legis-num>S. 2650</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20191021">October 21, 2019</action-date><action-desc><sponsor name-id="S253">Mr. Durbin</sponsor> (for himself and <cosponsor name-id="S307">Mr. Brown</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend part D of title XVIII of the Social Security Act to deliver a meaningful benefit and lower
			 prescription drug prices under the Medicare program.</official-title></form>
	<legis-body display-enacting-clause="yes-display-enacting-clause" id="HF79D8CEFB0174B1FAF8CDAA14CEC087F" style="OLC">
 <section display-inline="no-display-inline" id="HD70DE349A9B34CF29BA3C7313D19D3B8" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicare Prescription Drug Savings and Choice Act of 2019</short-title></quote>.</text> </section><section id="H83E397FA4DE749189A5F8EDC5FF813E0"><enum>2.</enum><header>Establishment of Medicare operated prescription drug plan option</header> <subsection id="H961D7348AA4A46788D7A1B0CCE70FAC3"><enum>(a)</enum><header>In general</header><text>Subpart 2 of part D of title XVIII of the Social Security Act is amended by inserting after section 1860D–11 (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-111">42 U.S.C. 1395w–111</external-xref>) the following new section:</text>
 <quoted-block act-name="Social Security Act" id="HAF045868058F4D0CBF4A66DBBD9308D1" style="traditional"><section id="H613CDF6F75BF49609EA5757D902A90D1"><enum>1860D–11A.</enum><header>Medicare operated prescription drug plan option</header><subsection commented="no" display-inline="yes-display-inline" id="HB5688214D0CD4C27B81F339DF8C82682"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Notwithstanding any other provision of this part, for each year (beginning with 2021), in addition to any plans offered under section 1860D–11, the Secretary shall offer one or more Medicare operated prescription drug plans (as defined in subsection (d)) with a service area that consists of the entire United States and shall enter into negotiations in accordance with subsection (c) with pharmaceutical manufacturers to reduce the purchase cost of covered part D drugs for eligible part D individuals who enroll in such a plan.</text>
 </subsection><subsection id="idc7c637dec0434b7b8023445a3f9e9e3e"><enum>(b)</enum><header>Enrollment</header><text>Notwithstanding subparagraphs (C) and (D) of section 1860D–1(b)(1), a Medicare operated prescription drug plan offered under this section shall serve as the default prescription drug plan for all part D enrollees unless another prescription drug plan is selected.</text>
 </subsection><subsection id="HA5861C8DD0E24916BE07CC7D572CF8F3"><enum>(c)</enum><header>Negotiations</header><text display-inline="yes-display-inline">Notwithstanding section 1860D–11(i), for purposes of offering a Medicare operated prescription drug plan under this section, the Secretary shall negotiate with pharmaceutical manufacturers with respect to the purchase price of covered part D drugs in a Medicare operated prescription drug plan and shall encourage the use of more affordable therapeutic equivalents to the extent such practices do not override medical necessity as determined by the prescribing physician. To the extent practicable and consistent with the previous sentence, the Secretary shall implement negotiation and incentive strategies similar to those used by other Federal purchasers of prescription drugs to reduce the purchase cost of covered Part D drugs, and other strategies, as described in subsection (f), which may include the use of a pricing scale based on an international price index.</text>
 </subsection><subsection id="HCA0F640FC43846728EF38C4BAE7A2020"><enum>(d)</enum><header>Medicare operated prescription drug plan defined</header><text>For purposes of this part, the term <term>Medicare operated prescription drug plan</term> means a comprehensive prescription drug plan that offers qualified prescription drug coverage and access to negotiated prices described in section 1860D–2(a)(1)(A). Such a plan may offer supplemental prescription drug coverage in the same manner as other qualified prescription drug coverage offered by other prescription drug plans.</text>
						</subsection><subsection id="HC92C5A61DB4741628FB3D2BD2EAA9A4B"><enum>(e)</enum><header>Monthly beneficiary premium</header>
 <paragraph id="HBB93687A38CD4E9E838D167ECC2A51B8"><enum>(1)</enum><header>Qualified prescription drug coverage</header><text>The monthly beneficiary premium for qualified prescription drug coverage and access to negotiated prices described in section 1860D–2(a)(1)(A) to be charged under a Medicare operated prescription drug plan shall be uniform nationally. Such premium for months in 2021 and each succeeding year shall be based on the average monthly per capita actuarial cost of offering the Medicare operated prescription drug plan for the year involved, including administrative expenses.</text>
 </paragraph><paragraph id="H07CE8EA529CA444EBCDF493130B265D5"><enum>(2)</enum><header>Supplemental prescription drug coverage</header><text>Insofar as a Medicare operated prescription drug plan offers supplemental prescription drug coverage, the Secretary may adjust the amount of the premium charged under paragraph (1).</text>
							</paragraph></subsection><subsection id="HAE50F5450C8E49D3B8AD5D84F3E9459C"><enum>(f)</enum><header>Use of negotiation and benefit design incentives</header>
 <paragraph id="HBD1D3025B97145EAB21A707CF6385AA0"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">With respect to the operation of a Medicare operated prescription drug plan and in negotiating with respect to the purchase price of covered part D drugs in such plan, the Secretary shall reward value, increase appropriate use of drugs, and ensure patient safety and access to medications.</text>
 </paragraph><paragraph id="HE905030A77A24353A1E518C2437023FE"><enum>(2)</enum><header>Role of AHRQ</header><text display-inline="yes-display-inline">The Director of the Agency for Healthcare Research and Quality, in coordination with the Administrator of the Centers for Medicare &amp; Medicaid Services, shall be responsible for assessing the clinical benefit of covered part D drugs and making recommendations to the Secretary regarding the negotiated prices of covered drugs and any appropriate tiering or incentive strategies under the plan. In conducting such assessments and making such recommendations, the Director shall carry out the following activities:</text>
 <subparagraph id="id4921aeaedf9845f1b50c5c56b3479e70"><enum>(A)</enum><text>Consider the comparable international price of such drugs based upon the median retail list price of such drug (which shall be, as practicable, the volume-weighted price for comparable units and dosage forms) among a category of at least the following peer reference countries: Canada, the United Kingdom, France, Japan, Australia, and Germany.</text>
 </subparagraph><subparagraph id="H376B541B5B3949C4BF12F2CEFE3E0363"><enum>(B)</enum><text>Consider safety concerns and post-market data, including those identified by the Food and Drug Administration and from national health registries.</text>
 </subparagraph><subparagraph id="H5C45BFD5F70B420C964D94CF0734EEAF"><enum>(C)</enum><text display-inline="yes-display-inline">Use available data and evaluations, including from research supported by the National Institutes of Health, with priority given to randomized controlled trials, to examine clinical effectiveness, comparative effectiveness, safety, and enhanced compliance with a drug regimen.</text>
 </subparagraph><subparagraph id="HEAAEAF97332D4194B57C47247DE1F63E"><enum>(D)</enum><text>Use the same classes of drugs developed by United States Pharmacopeia for this part.</text> </subparagraph><subparagraph id="HBCF3021C55CE49D2AA79AD75BAAA5A8E"><enum>(E)</enum><text>Consider evaluations made by—</text>
 <clause id="HE53DF41F08B94C57B0F575853BF4EFAE"><enum>(i)</enum><text>the Director under section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003;</text>
 </clause><clause id="H360A32710DA94B6EA54A0C1F5E643DA0"><enum>(ii)</enum><text>other Federal entities, such as the Secretary of Veterans Affairs; and</text> </clause><clause id="H83E87199867B4EA796AD5A8C7B874947"><enum>(iii)</enum><text>other private and public entities, which may include the Drug Effectiveness Review Project and Medicaid programs.</text>
 </clause></subparagraph><subparagraph id="id83E5ADEB441B450DACF38DCCDB3E8C34"><enum>(F)</enum><text>Consider recommendations made by the advisory committee pursuant to paragraph (3)(F).</text> </subparagraph><subparagraph id="idCDDE577E76564E1BA2855CF91A5925EB"><enum>(G)</enum><text>Recommend to the Secretary those drugs in a class that provide a greater clinical benefit, including fewer safety concerns or less risk of side effects, than another drug in the same class.</text>
								</subparagraph></paragraph><paragraph id="HE82D6DFCBD034D1CB557852F600D0E8D"><enum>(3)</enum><header>Use of advisory committee</header>
 <subparagraph id="id0119F23EB06B4D51BD265F32D0887865"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall establish and appoint an advisory committee (in this paragraph referred to as the <term>advisory committee</term>)—</text>
 <clause id="H3C6B92BEF51A4581A2CD889F78530F86"><enum>(i)</enum><text display-inline="yes-display-inline">to review petitions from drug manufacturers, health care provider organizations, patient groups, and other entities regarding negotiated prices; and</text>
 </clause><clause id="HD29920A7ED87480BA9F9D3839AF35BD3"><enum>(ii)</enum><text>to recommend any changes in order to further negotiations with respect to such prices.</text> </clause></subparagraph><subparagraph id="H4CA184E985904FD38100FE8C50EC57BC"><enum>(B)</enum><header>Composition</header><text display-inline="yes-display-inline">Subject to subparagraph (C), the advisory committee shall be composed of 9 members and shall include representatives of physicians, pharmacists, consumers, and others with expertise in evaluating prescription drugs. The Secretary shall select members based on their knowledge of pharmaceuticals and the Medicare population. Members shall be deemed to be special Government employees for purposes of applying the conflict of interest provisions under section 208 of title 18, United States Code, and no waiver of such provisions for such a member shall be permitted.</text>
								</subparagraph><subparagraph id="id0589F9623DF841618A5C071672E86BE9"><enum>(C)</enum><header>Banned individuals</header>
 <clause id="idB66B2707C7294F2598E7FAC950CEA02B"><enum>(i)</enum><header>Drug company lobbyists</header><text>No former registered drug manufacturer lobbyist—</text> <subclause id="idCA55F792B75D41A18499B436C679DF7E"><enum>(I)</enum><text>may be appointed to the advisory committee; or</text>
 </subclause><subclause id="id47064548B82642BCB256039639839BA7"><enum>(II)</enum><text>may be employed by the advisory committee during the 6-year period beginning on the date on which the registered lobbyist terminates its registration in accordance with section 4(d) of the Lobbying Disclosure Act of 1995 (<external-xref legal-doc="usc" parsable-cite="usc/2/1603">2 U.S.C. 1603(d)</external-xref>) or the agent terminates its status, as applicable.</text>
 </subclause></clause><clause id="idF472C17C6F7B4C3A8E242C4FD482BA9A"><enum>(ii)</enum><header>Senior executives of law-breaking companies</header><text>No former senior executive of a covered entity (as defined in clause (iii))—</text> <subclause id="id93F8CEEA0C044009B2E96891899D8829"><enum>(I)</enum><text>may be appointed to the Advisory Committee; or</text>
 </subclause><subclause id="id840743CF15B04B6688E5587D2C925739"><enum>(II)</enum><text>may be employed by the Advisory Committee during the 6-year period beginning on the later of—</text> <item id="id79EBC49224F74099ADF11DDA6425CA14"><enum>(aa)</enum><text>the date of the settlement described in item (aa) of clause (iii)(II); or</text>
 </item><item id="id3EE51162C5B141E5A0D1E5C0C429F698"><enum>(bb)</enum><text>the date on which the enforcement action described in item (bb) of such clause has concluded.</text> </item></subclause></clause><clause id="idB060B2FD24E8488F832D778A031A3670"><enum>(iii)</enum><header>Covered entity</header><text>The term <term>covered entity</term> means any entity that is—</text>
 <subclause id="idC485B865356B4D5A870B0E600959A5A5"><enum>(I)</enum><text>a drug manufacturer; and</text> </subclause><subclause id="id92C98618DD3D42A6B5C6A42A2A293411"><enum>(II)</enum><item commented="no" display-inline="yes-display-inline" id="id097A29383A304D31910EFED52EF0197B"><enum>(aa)</enum><text>operating under Federal settlement including a Federal consent decree; or</text>
 </item><item id="id4AD297F087764F8DA2B240AF32E21BFB" indent="up1"><enum>(bb)</enum><text>the subject of an enforcement action in a court of the United States or by an agency.</text> </item></subclause></clause></subparagraph><subparagraph id="H0901E0B304BA401197D91A1D075CF4AE"><enum>(D)</enum><header>Consultation</header><text>The advisory committee shall consult, as necessary, with physicians who are specialists in treating the disease for which a drug is being considered.</text>
 </subparagraph><subparagraph id="HAA1C578E34854DF298187585A196F53C"><enum>(E)</enum><header>Request for studies</header><text display-inline="yes-display-inline">The advisory committee may request the Agency for Healthcare Research and Quality or an academic or research institution to study and make a report on a petition described in subparagraph (A)(i) in order to assess cost effectiveness, clinical effectiveness, comparative effectiveness, safety, and compliance with a drug regimen.</text>
 </subparagraph><subparagraph id="H03C9E1E83A5242CCBE1D73D8362D6B2D"><enum>(F)</enum><header>Recommendations</header><text>The advisory committee shall make recommendations to the Director of the Agency for Healthcare Research and Quality regarding the appropriate price at which to begin negotiations on a part D drug pursuant to this section.</text>
 </subparagraph><subparagraph id="HCD827CB038B14A5EA8E5C8FB6DEDFE4A"><enum>(G)</enum><header>Limitations on review of manufacturer petitions</header><text display-inline="yes-display-inline">The advisory committee shall not review a petition of a drug manufacturer under subparagraph (A)(i) with respect to a covered part D drug unless the petition is accompanied by the following:</text>
 <clause id="H51A27397ACD74E1F98B96C92BFC573DF"><enum>(i)</enum><text display-inline="yes-display-inline">Raw data from clinical trials on the safety and effectiveness of the drug.</text> </clause><clause id="H13CB97B416C04899AA84635473E022FD"><enum>(ii)</enum><text>Any data from clinical trials conducted using active controls on the drug or drugs that are the current standard of care.</text>
 </clause><clause id="H5D072BB4F142423988EE8962771114CF"><enum>(iii)</enum><text>Any available data on comparative effectiveness of the drug.</text> </clause><clause id="HA9C9CFB783C84D2F84C5DEE147092957"><enum>(iv)</enum><text>Any other information the Secretary requires for the advisory committee to complete its review.</text>
 </clause></subparagraph></paragraph></subsection><subsection id="H790839DA559544399A22519BD890757C"><enum>(g)</enum><header>Informing beneficiaries</header><text display-inline="yes-display-inline">The Secretary shall take steps to inform part D eligible individuals not previously enrolled in a Medicare operated drug plan (including such individuals who are newly eligible to enroll under this part) regarding the enrollment of such individual in a Medicare operated drug plan in accordance with this section, including providing information in the annual handbook and adding information to the official public Medicare website related to prescription drug coverage available through this part.</text>
 </subsection><subsection id="H1653B7D9FB594EDE997230EE75C5F1E9"><enum>(h)</enum><header>Application of all other requirements for prescription drug plans</header><text>Except as specifically provided in this section, any Medicare operated drug plan shall meet the same requirements as apply to any other prescription drug plan, including the requirements of section 1860D–4(b)(1) relating to assuring pharmacy access.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection id="HC3031399E383488A83A36D8EDAFF24E7"><enum>(b)</enum><header>Conforming amendments</header>
 <paragraph id="H1B5D9DA047494ACAB7C14BB3D4C8D2E5"><enum>(1)</enum><text>Section 1860D–3(a) of the <act-name parsable-cite="SSA">Social Security Act</act-name> (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-103">42 U.S.C. 1395w–103(a)</external-xref>) is amended by adding at the end the following new paragraph:</text> <quoted-block act-name="Social Security Act" id="HCA983C27366E4F70A1811D9F990B2692"> <paragraph id="H4DB10DFF996D4EB49F66E2BC25E7282A"><enum>(4)</enum><header>Availability of the medicare operated prescription drug plan</header><text>A Medicare operated prescription drug plan (as defined in section 1860D–11A(d)) shall be offered nationally in accordance with section 1860D–11A.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph display-inline="no-display-inline" id="HCAFB12AC49A14E3A82334861A5DE4655"><enum>(2)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H70DCA074335E45B5A8095EBCC6B46880"><enum>(A)</enum><text>Section 1860D–3 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-103">42 U.S.C. 1395w–103</external-xref>) is amended by adding at the end the following new subsection:</text>
						<quoted-block id="H46F72C53D9FF47309A0E7E26E2FD8DE6" style="OLC">
 <subsection id="HCE34A08679DA452ABCAFC811548F4C38"><enum>(c)</enum><header>Provisions only applicable in 2006 through 2020</header><text>The provisions of this section shall only apply with respect to 2006 through 2020.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </subparagraph><subparagraph id="H0E43A64328984EC393A7493140D6BC52" indent="up1"><enum>(B)</enum><text>Section 1860D–11(g) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-111">42 U.S.C. 1395w–111(g)</external-xref>) is amended by adding at the end the following new paragraph:</text>
						<quoted-block id="H39BACE287B3C4FBB82A38E39D966A396" style="OLC">
 <paragraph id="H246F66D57DF24CBAADCD1CF036F7E256"><enum>(8)</enum><header>No authority for fallback plans after 2020</header><text>A fallback prescription drug plan shall not be available after December 31, 2020.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subparagraph></paragraph><paragraph id="HCC1EAB9DB27D4FF0A08C6B869D4AE2F5"><enum>(3)</enum><text>Section 1860D–13(c)(3) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-113">42 U.S.C. 1395w–113(c)(3)</external-xref>) is amended—</text>
 <subparagraph id="H368706C4039547619B973A2D49606F52"><enum>(A)</enum><text>in the heading, by inserting <quote><header-in-text level="paragraph" style="OLC">and Medicare operated prescription drug plans</header-in-text></quote> after <quote><header-in-text level="paragraph" style="OLC">Fallback plans</header-in-text></quote>; and</text> </subparagraph><subparagraph id="H24C0059CAFBD4C4AB21EBF519B4CFA67"><enum>(B)</enum><text display-inline="yes-display-inline">by inserting <quote>or a Medicare operated prescription drug plan</quote> after <quote>a fallback prescription drug plan</quote>.</text>
 </subparagraph></paragraph><paragraph id="HB932D7B9750B4C078135115818795B07"><enum>(4)</enum><text display-inline="yes-display-inline">Section 1860D–16(b)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-116">42 U.S.C. 1395w–116(b)(1)</external-xref>) is amended—</text> <subparagraph id="H2F1664963E8A48A89E0D56CC1B1637B7"><enum>(A)</enum><text>in subparagraph (C), by striking <quote>and</quote> after the semicolon at the end;</text>
 </subparagraph><subparagraph id="HB29EE6A5D7DA44B1A2F1CD60F82DD653"><enum>(B)</enum><text>in subparagraph (D), by striking the period at the end and inserting <quote>; and</quote>; and</text> </subparagraph><subparagraph id="H7A7186E992E54389B1FC1C0A87057857"><enum>(C)</enum><text>by adding at the end the following new subparagraph:</text>
						<quoted-block id="HF95FE5FC1FFB40E7A1A5881DE72CF364">
 <subparagraph id="H8B134796AC0843969B0C8FB9DB34AA9D"><enum>(E)</enum><text>payments for expenses incurred with respect to the operation of Medicare operated prescription drug plans under section 1860D–11A.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="HC50799BBB84A4E30A0ACF04CA2B76B04"><enum>(5)</enum><text display-inline="yes-display-inline">Section 1860D–41(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-151">42 U.S.C. 1395w–151(a)</external-xref>) is amended by adding at the end the following new paragraph:</text>
					<quoted-block id="H2CFA40EF8CF949EC893DDA9898222ABE">
 <paragraph id="HC4383114B69743AF8327C672C177D61E"><enum>(19)</enum><header>Medicare operated prescription drug plan</header><text>The term <term>Medicare operated prescription drug plan</term> has the meaning given such term in section 1860D–11A(d).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </paragraph></subsection><subsection id="id71f9d229beee4920ab7509a32d1ee0fa"><enum>(c)</enum><header>Rule of construction</header><text>Nothing in this section shall be interpreted to supersede any other negotiation authority granted to the Secretary under Federal law with respect to prescription drug prices.</text>
 </subsection></section><section id="H860B6B2568BC4781BB0142E6F37985DD"><enum>3.</enum><header>Improved appeals process under the Medicare operated prescription drug plan</header><text display-inline="no-display-inline">Section 1860D–4(h) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1305w-104">42 U.S.C. 1305w–104(h)</external-xref>) is amended by adding at the end the following new paragraph:</text>
			<quoted-block display-inline="no-display-inline" id="HBCC273BB421F457D93431B422B65F1AA" style="OLC">
				<paragraph id="H9AD90DF77A4E4DF0BCB6D7ACEDB97A1A"><enum>(4)</enum><header>Appeals process for Medicare operated prescription drug plan</header>
 <subparagraph id="H282E5062AE8547C083B4A11C65C0F1A9"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall develop a well-defined process for appeals for denials of benefits under this part under the Medicare operated prescription drug plan (as defined in section 1860D–11A(d)). Such process shall be efficient, impose minimal administrative burdens, and ensure the timely procurement of medications. Medical necessity shall be based on professional medical judgment, the medical condition of the beneficiary, and other medical evidence.</text>
 </subparagraph><subparagraph id="HC692CFA4691C44C79C3A0FB07E806B4C"><enum>(B)</enum><header>Consultation in development of process</header><text>In developing the appeals process under subparagraph (A), the Secretary shall consult with consumer and patient groups, as well as other key stakeholders, to ensure the goals described in subparagraph (A) are achieved.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill>


